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Best Vaccine Induced CD4+ and CD8+ T-Cells (Humans):






















Ref:  HVTN-080 Study; Kalams et al. 2011 HVTN Annual Meeting











D, D, D, M, M 0, 28, 56, 112, 140 70 33
HVTN 205-
GeoVax
DNA',MVA-B D, M, M, M 0, 56,             112, 140 73 27
Inovio DNA-EP:  Better & faster CD8+ T cell responses than viral 
vectors and/or complex prime-boost regimens
Page 3
HVTN 077-VRC Ad35. Ad5 Ad35, Ad5 0,                                    168 16 35
DNA', Ad5 D, D, D, Ad5 0, 28, 56, 168 45 47
(Ad5 sero-) DNA', Ad35 D, D, D, Ad35 0, 28, 56, 168 23 36
(Ad5 sero+) DNA', Ad35 D, D, D, Ad35 0, 28, 56, 168 23 12
INOVIO’s 
DNA+EP
DNA/IL-12/EP D, D, D 0, 28, 84 81 52
Source:  McElrath - Compilation of HVTN study results
>90%
HIV Therapy:  PENNVAX™-B Phase I Study (HIV-001)
• Open label Phase I clinical trial (therapy) - UPenn
• Four vaccinations over 4 months (0, 4, 8, 16 weeks)
• 12 vaccinated subjects:
• PENNVAX™-B (1 mg each of EnvB, Gag, Pol) + IM EP
• On HAART; Undetectable plasma viral load (< 75 copies/mL)
• CD4 T lymphocyte counts > 400 cells/uL with nadir > 200 cells/uL
T-cell Responses
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• T-cell immune responses superior to previously-tested HIV  
DNA vaccines in HIV+ population
by IFN-g ELISpot Assay
Vaccine induced T-cell responses 
(2 SD above prevacc. ELISpot levels)
Vaccine + EP
At least 1 Ag 75% (9/12)
2 or more Ag 50% (6/12)
Responses predominantly CD8+ T Cells
Integrated Synthetic Vaccine Platform: 
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Revolutionizing Vaccines Through:
• Unparalleled safety profile
• Greater potency than viral vectors in primates and in humans (T-cells & Abs)
• Only platform to yield CD8+ effector T-cells in humans without anti-vector serology
• No vector induced responses – repeat boosts; multiple/combination vaccines; 
older/younger people
• Manufacturing advantages:  Rapid, scalable, stable, stockable
Superior Vaccine Delivery Using Electroporation
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Display of Green Fluorescence Protein (GFP) gene expression 
after electroporation delivery  into rabbit muscle




DNA/EP by the Numbers
• Number of DNA Trials:  > 3,600
• Number of study participants:  Est. > 50,000+; > 150,000 Imm.; 
decades of follow up
• Number of DNA + EP Trials: 32
• Number of DNA + EP study participants: >1,600 (enrolled/scheduled)
• Number of EP vaccinations:  > 4,800+ (estimated)
• Inovio Figures (enrolled); # Vaccinations:
• IM EP: 300+; 1000+
Page 8
• ID EP: 120+;  280+ 




1466 US; 530 EU
2/2012:
3631 studies worldwide
1938 US; 719 EU
HPV & HPV Associated Cancers
• USA:  Annual incidence of HPV associated cancers
> 20,000 in women; > 11,000 in men
• Cervical Cancer > 99% HPV associated (> 70% are 16/18)
• Merck (Gardasil) & GSK (Cervarix): >$1.5 B in annual sales
• Worldwide: Annually
• ~500,000 new cases cervical cancer – 50% fatal
• 2nd largest cancer killer of women  > 250k deaths
• USA: Annually
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• 3M  ASCUS (atypical cells) with HPV
• 250K CIN 2/3 (stage prior to cancer) with HPV16/18
• 13,000 cervical cancer; 5,000 deaths
• $6 B spent: cervical cancer diagnosis and treatment
• Surgery/ablation invasive + feared impact on childbirth
• Head and Neck (HNSCC) ~ 23.5% – 35.6% associated with HPV
• HPV 16 (68-86%); HPV 18 (1-8%)
• USA Annually: >40,000 new cases; >7,800 deaths
• 5 year survival: 26.5% - 81.8% (median 59.1%)
Need for less-invasive, more readily distributable treatment of cervical dysplasia 
and cancer
• VGX-3100 targets E6 + E7 oncogenes which transform HPV-
infected cells into precancerous & cancerous cells
• HPV Types 16 and18
VGX-3100: Cervical Dysplasia/Cancer Therapy
IgELS
HPV-16 E6 HPV-16 E7
Endoproteolytic 
cleavage site




* Deletions or mutations important for p53 binding and degradation
 Mutations in Rb binding site
IgELS
HPV-18 E6 HPV-18 E7
Endoproteolytic 
cleavage site





6.0 mg/mL 6.0 mg/mL
Purity (A260/280) 2.0 2.0
Host-Cell RNA ≤ 0.1% 1%
Host-Cell Protein ≤ 0.1% ≤ 0.1%
Host-Cell DNA ≤ 0.001% ≤ 0.001%
VGX-3100 (HPV)
High Concentration, High Purity Formulations
pGX2001 pGX2002 pGX2003
9.2 mg/mL 8.1 mg/mL 8.5 mg/mL
2.0 2.0 1.9
≤ 0.06% ≤ 0.08% ≤ 0.07%
≤ 0.03% ≤ 0.04% ≤ 0.04%
≤ 0.001% ≤ 0.001% ≤ 0.001%
VGX-3400 (Influenza)
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Endotoxin ≤ 0.1 EU/mg ≤ 0.1 EU/mg
Microbial Limits Absent Absent
1.1 EU/mg ≤ 1.2 EU/mg ≤ 1.9 EU/mg
Absent Absent Absent
Now routinely achieve upwards 
of 10+ mg/mL to support multi-
plasmid formulations
































1.    pVAX
Ref:  Yan et al (2009) Vaccine
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2.    pConE6E7
3.    pE7
Note:  TC1 Challenge model - Lung Epit. Cell line with HPV-16 – E6, E7
HPV-001/002: Phase 1 Study - Safety & Immunogenicity
o Combination of HPV DNA vaccine delivered IM using Cellectra® EP device 
– HPV 16, 18 (E6 + E7)
o Indication: Treatment of HPV types 16 and/or 18 associated CIN2/3
Dose(mg)Number of PatientCohort
3 X 2 Plasmids63
1 X 2 Plasmids62
0.3 X 2 Plasmids61
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Patients with a history of CIN 2/3 previously treated by LEEP procedure were 
vaccinated 3x at 0, 1, 3 mo.
Serum and PBMC samples collected at multiple time points before and post 
immunization to evaluate immune responses.
Boosted at month 
16+
HPV-002
HPV Clinical Reports  - Previous Studies:
o MVA – based HPV E6/E7 vaccines from Transgene: Phase IIa (n = 21) completed; Phase IIb (n = 200) 
near completion
o Ad5, SFV (Semliki Forest virus)-based HPV E6/E7 vaccines
o Protein/Peptide-based vaccines – Recent encouraging data in VIN (Malief et al)
o Listeria-based vaccines 
o DNA-based vaccines (TC Wu) - Use gene gun techniques to introduce HPV DNA vaccines directly 
into APCs; However…
o Low immune responses observed - cultured ELISpots needed to see cellular responses
- no antibody responses induced
HPV: Therapeutic Vaccines
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Trimble C L et al. Clin Cancer Res 2009;15:361-367
IM injection: 5/15 patients showed E7-specific responses, 2/15 patients showed E6-specific 
responses, the T cell responses required culture to observe. Vaccination did not induce Abs 
Improving Immune potency important
HPV001:  Best Vaccine Induced IFN-γ ELISpot Responses to HPV 
Peptides and HPV-Specific CTL Activity (GrzB Assay)  (Humans)
IFN-γ ELISpot Responses:  
• 5/6 positive
• All 4 antigens represented
• CD4+ & CD8+ T-cells
































18 E6 16 E7
18 E7
18 E6
HPV-specific killing phenotype:  
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18 E7
18 E6
Flow Cytometry – HPV-001 Quantitative Killing Assay
Morrow, Inovio
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Whole PBMCs are effectors.  Killing Magnitude scales with 
the number of CTLs.  
Flow Cytometry – HPV-001 Identification and Analysis of Tregs
Morrow, Inovio
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No association between Tregs (PBMC CD4/CD25hi/FoxP3+)  present pre-vac. 
and response rate in ELISpot, CTL ICS or Quantitative Killing
VGX-3100/EP Phase 1 Study Summary
• IM VGX-3100 + CELLECTRA™ EP Safety
• No safety concerns to date, well tolerated
• No discontinuations or  related SAEs or Gr 3 or 4 AEs
• Mean VAS 6.2/10 decreases to 1.4/10 within 10 mins
• Antibodies against all 4 antigens with high titers in 15/18 
(83%) and Western Blot confirmation in all persist to 9 mos
• Antigen-specific cellular responses to HPV16,18 E6, E7
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• 13/18 (72%) POS by IFN-γ ELISpot (>50 SFU/106 PBMC)
• Increase w/ dose up to > 2500 SFU/106 PBMC for 1 Ag, > 5,670 
SFU/106 PBMC for all 4 antigens
• 5 subjects responded to all 4 antigens
• Responses persist to 9 months after primary series
• 4th dose boosts T cell responses up to > 2 years
• HLA DR+ / CD38+ CD8+ T cells release Granzyme B / perforin for cell 
killing – more sensitive than ELISpot?
Phase II Study Design for VGX-3100 (CIN2/3)
• Randomized, blinded study: VGX-3100/IM EP vs. placebo
• Patients: CIN2/3 (high grade cervical dysplasia) 
• + HPV16 and/or 18 (cause 70% of cervical cancers)
• 1˚endpoint: CIN 2/3 or CIN 3 lesion clearance to CIN 1 or less 6 months 
post 3rd dose (based on biopsy)
• 80% Power to detect efficacy >25% difference in regression rate between 
Vaccine and Placebo : ~150 patients, 3:1 Vaccine/placebo
• Timeline: total duration: ~2 ½ years
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• Launched: 2Q 2011 
• Enrollment:1 – 1½ years
• ~18 month protocol: 3 month treatment + 6 
month endpoint + 9 month LTFU
Product Opportunities for HPV 
Serotypes Beyond 16/18
HPV 33, 45 - Cancer
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HPV 6, 11 – Genital Warts
Potential for Broader and/or Targeted Coverage
Ref:  Smith et al Int. J. Cancer (2007) 
HPV types 16 or 18 account for > 70% ICC and > 55% HSIL worldwide
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Ref:  Shin et al. Hum. Vaccines 
Immunotherapy 2012
CD8+ Ag Specific T-cells
(By ICS)

























Next Generation DNA Delivery Systems for 
T- and B-cell Targets and  Prophylactic Vaccination
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Intramuscular EP Intradermal EP
MID SEP
Hair Follicle Hair Follicle
Surface EP Device – Transfection localization
Page 25Broderick et al, Gene Therapy 2011
SEP Device GFP Expression Kinetics
1 hour                  2 hours             4 hours           8 hours                  24 hours                48 hours
Page 26
Upper  Panel – Gross guinea pig skin         
Middle Panel – Magnified guinea pig skin                
Lower Panel – Guinea pig skin sections 















































HAI titers following immunization with the surface ID device in NHP’s
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No associated tissue 
damage in guinea pig 
skin biopsies 
removed   3 days 
post treatment.
Majority of GFP 
transfection was 









































Percent survival following immunization with the surface ID device in mice
Broderick et al, Gene Therapy 2011
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Broderick et al, Molecular Therapy 2012
Some Issues of Conventional Vaccine Technologies
Conventional Vaccines
• Attenuation is an art form - ?
• Safety – Goldilocks paradox
• Atypical responses following 
vaccination (RSV, Measles)
• STEP:  Serology issues not understood
• Manufacturing complexity
• Cell substrates (Egg limitations, Cell 
line contamination, etc)
Some Novel At Risk Populations 
• Eczema
• Autoimmune  Diseases 
(treated – TNF inhibitors etc.)
• Pregnancy
• Increased elderly population
• Elderly travelers (Unique)




• Product Analytics - Complex
• Stability and Formulation
• Filling models – What is in the vial
• Building production plants at risk
Cancer Immune Therapies
• Older patients many vector immune
(Ad, pox, many others)
• Poorer ability to control live replication
• Poorer responses to non live antigens
Development of new vaccine technologies (DNA) are an 
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Public Health Agency, Canada
Gary Kobinger
Funding:
NIH/NIAID/DAIDS; MVI-PATH; DTRA; CDMRP; DOD
Clinical studies volunteers and sites
IM v. ID EP:  Clinical Tolerability Data (FLU-001/002)
FLU study:  Interim data from volunteers who received 
2x IMEP Prime followed by 2x IDEP Boost




T10 p = 0.0084
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Inovio DNA-EP:  
• Generally well tolerated 
• No Grade 3 or 4 AEs/SAEs related to vaccine
• No biodistribution/integration concerns noted to-date
